Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02149303 · ClinicalTrials.gov registry record
Management of Major Bleeding Events in Atrial Fibrillation Patients Using Pradaxa
A clinical trial, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- 191
- Enrollment target
NCT02149303 is a clinical trial that has completed, run by Boehringer Ingelheim. The registered enrollment target is 191 participants.
The verdict
NCT02149303 has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- 191 participants
- Enrollment target
Study Summary
This study is being conducted to collect data on the management of major bleeding events occurring in patients with atrial fibrillation taking dabigatran etexilate.
Interventions
- DRUG Dabigatran 75 mg
- DRUG Dabigatran 150 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 191 participants |
| Start Date | 2014-06 |
| Est. Completion | 2015-03 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02149303
The ClinicalTrials.gov registry entry for NCT02149303 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 191 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Dabigatran 75 mg is the first listed.
NCT02149303 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02149303 about?
NCT02149303 is a clinical study titled "Management of Major Bleeding Events in Atrial Fibrillation Patients Using Pradaxa". This study is being conducted to collect data on the management of major bleeding events occurring in patients with atrial fibrillation taking dabigatran etexilate.
What is the current status of trial NCT02149303?
This trial is currently completed. The enrollment target is 191 participants. The study started on 2014-06. Estimated completion is 2015-03.
What interventions are being tested in trial NCT02149303?
The interventions under investigation include: Dabigatran 75 mg (DRUG), Dabigatran 150 mg (DRUG).
Who is sponsoring clinical trial NCT02149303?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.